Hogan Lovells Digital Health brochure 2024 - Flipbook - Page 4
Hogan Lovells
Artificial Intelligence
Companies pursuing AI technologies
must realize that while the life
sciences and health care industries
are embracing this technology, the
regulatory landscape is still finding its
footing. That’s where we can help.
In the life sciences, this year has seen AI
achieve some impressive feats. For example,
AI is being used to innovate compounds for
medicinal use, and those compounds are in
the process of being put forward for regulatory
approval. However, questions are being raised
by regulators worldwide as to the extent to
which IP and regulatory protections can and/
or should be available for innovations where
AI has been involved. Regulators are in the
process of considering any changes that might
need to be made to the law. The answers to
these questions could see monumental shifts
in the way that R&D e昀昀orts are managed
and/or compensated. Hogan Lovells has
been advising clients on the present IP and
regulatory landscape. Hogan Lovells has also
been at the coalface of potential changes in
the law, advising clients on what the future
could hold, as well as how to be prepared. Our
highly experienced cross-practice teams are
able to advise on the regulatory landscape for
operators in the life sciences industry.
4
